High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
72.56K
+68.74%
-0.621
+29.43%
622.22K
+36.45%
-0.671
+49.17%
0.00
-100%
-0.705
+30.56%
Estimates Revision
The market is revising Upward the revenue expectations for CG Oncology, Inc. (CGON) for FY2025, with the revenue forecasts being adjusted by 78.43% over the past three months. During the same period, the stock price has changed by 35.26%.
Revenue Estimates for FY2025
Revise Upward
+78.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.25%
In Past 3 Month
Stock Price
Go Up
+35.26%
In Past 3 Month
12 Analyst Rating
Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 70.09 USD with a low forecast of 55.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.730
Low
55.00
Averages
70.09
High
90.00
Current: 44.730
Low
55.00
Averages
70.09
High
90.00
Truist
Gregory Renza
Buy
initiated
$62
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$62
2025-11-24
initiated
Buy
Reason
Truist analyst Gregory Renza initiated coverage of CG Oncology with a Buy rating and $62 price target. The firm views Creto's high complete response rates, favorable tolerability, and differentiated durability as key attributes that could support robust market positioning for the company, the analyst tells investors in a research note. The potential expansion into intermediate-risk/IR NMIBC, or Non-Muscle Invasive Bladder Cancer, and additional high-risk settings represent a strategic approach that could broaden Creto's commercial opportunity, given the ongoing BCG - Bacillus Calmette Guerin - shortage, Truist added.
RBC Capital
Outperform
maintain
$53 -> $61
2025-11-17
Reason
RBC Capital
Price Target
$53 -> $61
2025-11-17
maintain
Outperform
Reason
RBC Capital raised the firm's price target on CG Oncology to $61 from $53 and keeps an Outperform rating on the shares. CG Oncology's Q3 update highlighted that its BLA filing is now underway, easing concerns about timing and keeping the company on track for a potentially strong non-muscle invasive bladder cancer launch with a more than $2.7B opportunity, the analyst tells investors in a research note. With additional Q4 catalysts ahead and a favorable safety/efficacy profile despite competitive questions, the outlook remains compelling, RBC says.
BofA
Buy
downgrade
$62 -> $60
2025-11-14
Reason
BofA
Price Target
$62 -> $60
2025-11-14
downgrade
Buy
Reason
BofA lowered the firm's price target on CG Oncology to $60 from $62 as the firm pushes back launch timing for creto to 2027 and updates operating expense expectation. BofA keeps a Buy rating on the shares. The firm notes that the company announced in their Q3 print that they have initiated their rolling BLA submission to the FDA for creto in HR BCG-unresponsive NMIBC. BofA continues to see an attractive setup heading into the BLA/potential approval given creto's durability and safety continue to shine.
JPMorgan
NULL -> Overweight
maintain
$41 -> $47
2025-09-26
Reason
JPMorgan
Price Target
$41 -> $47
2025-09-26
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on CG Oncology to $47 from $41 and keeps an Overweight rating on the shares. The firm rolled forward its price target.
Morgan Stanley
Overweight
upgrade
$56 -> $79
2025-09-17
Reason
Morgan Stanley
Price Target
$56 -> $79
2025-09-17
upgrade
Overweight
Reason
Morgan Stanley raised the firm's price target on CG Oncology to $79 from $56 and keeps an Overweight rating on the shares. The approval of Inlexzo and higher-than-expected price bolsters Morgan Stanley's confidence in creto's regulatory pathway ahead as well as peak sales potential, the analyst tells investors in a research note.
JonesResearch
NULL
to
Buy
initiated
$50
2025-09-08
Reason
JonesResearch
Price Target
$50
2025-09-08
initiated
NULL
to
Buy
Reason
JonesResearch initiated coverage of CG Oncology with a Buy rating and $50 price target. The late-stage company is developing an oncolytic virus, cretostimogene grenadenorepvec, in multiple settings of Non-Muscle Invasive Bladder Cancer, notes the analyst, who calls CG "a good bet in the bladder cancer space" with a strong cash position to fund several of trials through regulatory filings and "a fairly derisked drug with potentially best-in-class efficacy."
See All Ratings
Valuation Metrics
The current forward P/E ratio for CG Oncology Inc (CGON.O) is -16.36, compared to its 5-year average forward P/E of -17.82. For a more detailed relative valuation and DCF analysis to assess CG Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-17.82
Current PE
-16.36
Overvalued PE
-12.79
Undervalued PE
-22.85
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-13.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-7.17
Undervalued EV/EBITDA
-20.45
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3309.14
Current PS
0.00
Overvalued PS
4522.29
Undervalued PS
2096.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
CGON News & Events
Events Timeline
(ET)
2025-11-26
07:05:22
CG Oncology Names Rossi to Its Board of Directors
2025-11-14 (ET)
2025-11-14
08:02:01
CG Oncology anticipates sufficient cash to support operations through the first half of 2028.
2025-11-14
08:01:33
CG Oncology Announces Q3 EPS of 57c, Exceeding Consensus Estimate of 55c
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0b9aa6103fb8706c2efe7287aa6caefb7a44b889879284f2bfd653dbdf2e4b87.png)
Preview
4.0
11-28TipRanksThree Stocks with Significant Growth Potential, According to Top Analysts – 11/27/2025
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/be087abe950d3341ba19016809b5fe6bfe137dfbf15ec461315e2621e3846b7f.png)
Preview
5.0
11-26NewsfilterCG Oncology Appoints Christina Rossi to Board of Directors Amid BLA Initiation
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/20251126200253_d058250e3d0203ed0cb3b3929d5e4bc9.jpeg)
Preview
5.0
11-26GlobenewswireCG Oncology Appoints Christina Rossi to Board of Directors Amid BLA Initiation
Sign Up For More News
People Also Watch
FAQ
What is CG Oncology Inc (CGON) stock price today?
What is CG Oncology Inc (CGON)'s business?
What is the price predicton of CGON Stock?
What is CG Oncology Inc (CGON)'s revenue for the last quarter?
What is CG Oncology Inc (CGON)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CG Oncology Inc (CGON)'s fundamentals?
How many employees does CG Oncology Inc (CGON). have?